Sravan Kumar Emany, Chief Financial Officer at Beam Therapeutics Inc. (BEAM), sold 6,294 shares at $27.10 ($171K) on 2025-12-31, disclosed to the SEC on 2026-01-05.
Scheduled sale ($171k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| IRWD | BUY | 2023-09-18 | $600K | — | Filing → |
| IRWD | SELL | 2022-11-23 | $152K | — | Filing → |